Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

By Ghatnekar Ola   Hjalte Frida   Taylor Matthew  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite

Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib

By Mishima Y.  

Targeted Oncology, Vol. 1, Iss. 3, 2006-07 ,pp. : 168-171

Springer Publishing Company

Access to resources Recommend Favorite

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate

By Hardling Mats   Wei Yuan   Palmqvist Lars   Swolin Birgitta   Stockelberg Dick   Gustavsson Bengt   Ekeland-Sjöberg Kerstin   Wadenvik Hans   Ricksten Anne  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 349-358

Humana Press, Inc

Access to resources Recommend Favorite

ABCB1 haplotypes are associated with Pgp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib

By                    

Oncology Letters, Vol. 7, Iss. 4, 2014-01 ,pp. : 1313-1319

Spandidos Publications

Access to resources Recommend Favorite

Imatinib and chronic myeloid leukemia: close to the bone

By Terpos Evangelos  

Leukemia and Lymphoma, Vol. 54, Iss. 8, 2013-08 ,pp. : 1581-1582

Informa Healthcare

Access to resources Recommend Favorite